Vance Touts Trump Policies to Boost Truckers, Manufacturers, Economy

During back-to-back campaign stops in swing states on Aug. 28, Sen. JD Vance (R-Ohio) told workers that he and former President Donald Trump are championing policies that will boost trucking and manufacturing with the aim to improve the economy for all Americans.

“We want truckers to be empowered instead of throttled,” Vance told people gathered at Team Hardinger, a trucking and warehousing company in Erie, Pennsylvania.

Hours later, Vance, the Republican vice-presidential nominee, also campaigned in another battleground state, Wisconsin; there, he spoke at AmeriLux International, a manufacturer and distributor of building materials.

In both speeches, Vance pledged that if he and Trump win the Nov. 5 election, they will reverse policies that he said are hurting trucking, manufacturing, and the U.S. economy overall.

Read Full Article Here
 

Follow us

Read our latest news on any of these social networks!

Get latest news delivered daily!

We will send you breaking news right to your inbox


Have a tip? Let us know!

Recent Articles

  • by:
  • Source: Fox News
  • 03/14/2025
...
Chuck Schumer will vote to keep government open: 'For Donald Trump, a shutdown would be a gift'

Senate Minority Leader Chuck Schumer, D-N.Y., says he will vote to keep the government open, warning that a shutdown has worse consequences for Americans and would only empower President Donald Trump and Elon Musk further.

...
More than 2,000 laid off at Johns Hopkins University amid Trump budget cuts

Johns Hopkins University announced Thursday it's laying off over 2,000 employees amid budget cuts made by the Trump administration.

...
ICE: US Immigration Detention Maxed at 47.6K Detainees

U.S. immigration detention is filled to capacity at 47,600 detainees, a senior U.S. Immigration and Customs Enforcement official said on a call with reporters on Wednesday, adding that the Trump administration was seeking more bed space.

...
Yearly HIV prevention injection 'Lenacapavir' shows promise in clinical trial

Pain at the injection site was the most common adverse event, which was generally mild, resolved within one week.